Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population

Filipp Filippovich Vasilyev1,*, Diana Aleksandrovna Danilova1, Vladimir Sergeevich Kaimonov1, Yana Valerievna Chertovskih2, and Nadezda Romanovna Maksimova1

1Limited Liability Company “GeneDiag”, North-Eastern Federal University, Yakutsk, Russia. 2Republican hospital No. 3, Yakutsk, Russia.

Abstract

Allele frequencies of single nucleotide polymorphisms (SNPs) are variable among different populations; therefore the study of SNPs in ethnic groups is important for establishing the clinical significance of the screening of these polymorphisms. The main goal of the research is to study the polymorphisms of CYP2C9, CYP2C19, VKORC1, and SLCO1B1 in Yakuts. Genomic DNA from 229 Yakut subjects were analyzed by real-time polymerase chain reaction (PCR) (SLCO1B1 +521T > C, VKORC1 -1639G>A, CYP2C19 +681G>A, +636G>A, CYP2C9 +430C>T, +1075A>C). Genotype frequencies of polymorphisms in the population of the Yakuts were more characteristic of the Asian population. The results have been included in the software application “Lekgen” that we developed for the interpretation of pharmacogenetic testing. The data of our study obtained on frequency carriers of polymorphisms of genes SLCO1B1, CYP2C19, CYP2C9, VKORC1 among the Yakuts may be useful in developing recommendations for a personalized therapy.

Keywords: Polymorphism; Genotyping; Pharmacogenetics; Yakuts

INTRODUCTION

Currently, all over the world, there is a high incidence of adverse reactions to medications. Evidence suggests that drug therapies not accounting for interindividual differences are ineffective in 30-60% of patients (1,2). Personalized medicine is an approach based on patient-oriented methods of treatment and diagnostics. Personalized medicine allows us to use modern molecular genetic technologies to personalize the use of drugs. This will make the therapy safe, efficient and cost-effective. Applying the principles of personalized medicine will improve clinical outcomes for patients and help to achieve more effective use of health care resources (3). The most promising tool for clinical practice of personalized medicine is the pharmacogenetic testing that can identify the individual’s genetic characteristics that contribute to the pharmacological response (4,5). Some of the genes complexes determining drug metabolism are cytochrome P450 (CYP) genes. CYP P450 is a superfamily of enzymes that plays an important role in the metabolism and elimination of a wide range of medications (6). The CYP2C enzymes account for the metabolism of approximately 20% of therapeutic drugs (7). The main CYP2C isoforms, namely CYP2C9 (50% of the total CYP2C) and CYP2C19 (16% of the total CYP2C) are homologous and share more than 80% amino acid sequence identity (8,9). CYP2C19 is responsible for the metabolism of a range of clinically important drugs, namely clopidogrel, proton pump inhibitors, diazepam, imipramine, fluoxetine, tolbutamide, voriconazole. CYP2C19*2 and CYP2C19*3 alleles are responsible for the poor metabolizer phenotype (10). CYP2C9 is involved in the metabolism of drugs including warfarin, losartan, tolbutamide, phenytoin, nonsteroidal anti-inflammatory drugs, and antidepressants. CYP2C9*2 and CYP2C9*3 alleles cause defective CYP2C9 catalytic activity (10,11). Numerous groups of researchers have found that the vitamin K epoxide reductase

*Corresponding author: F. F. Vasilyev
Tel: 007 924 592 84 17, Fax: 007 4112 36 09 34
Email: vasilyevmd@gmail.com
complex 1 polymorphisms correlate with the therapeutic warfarin dose (12). Solute carrier organic anion transporter family member 1B1 (SLCO1B1) transports statins and metabolites from the blood stream into the cells of the liver. SLCO1B1*5 allele have demonstrated significant pharmacokinetic influence (13,14). It is well known that pharmacogenetic relevant alleles occur with varying frequencies among different ethnic populations (15). The study of single nucleotide polymorphisms (SNPs) in different ethnic groups is important to establish clinical relevance of screening for these SNPs to the evaluation of the efficacy and safety of pharmacotherapy for individuals around the world.

Yakuts are a population isolate in Asia and live in the North-Eastern part of Siberia in the Russian Federation. Yakuts emigrated from southern to northern Siberia in the 13th or 14th century AD and their population has expanded rapidly to >450 000 people in a restricted area. Yakuts are a population isolate that can provide a unique model for genetic studies (16,17). The genetic difference is one of the main causes of inter-individual differences in response to pharmacotherapy. Assessment of inter-individual differences in the genotype frequencies is very important for the Russian Federation because of its high multinationality. The purpose of this research is to study polymorphisms of genes associated with the metabolism of drugs. To achieve the goal, we analyzed the distribution of 6 polymorphisms at CYP2C9, CYP2C19, VKORC1, and SLCO1B1 genes in individuals of the Yakut ethnicity living in North-Eastern Siberia. Also the results of this study will be used for the correct interpretation of pharmacogenetic testing using our software application “Lekgen” (Limited Liability Company “GeneDiag”, Yakutsk, Russia).

**MATERIALS AND METHODS**

**Subject**

Whole blood samples from 229 unrelated healthy individuals comprising 120 males and 109 females were obtained from the biological sample bank of Limited Liability Company “GeneDiag” (Yakutsk, Russia) and sampling carried out from a Yakut ethnicity subjects (Asian ethnic origin) from the Yakutia (North-Eastern Siberia, Russia). The mean age was 38.5 ± 7.7 years (range: 21-57 years).

The main exclusion criteria were standard for blood donors in the Russian Federation. Research was performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and was approved by the local ethics committee of the FSBI “Yakut Scientific Centre of Complex Medical Problems”. All individuals provided informed consent before the study was carried out.

**Genotyping methods**

Genomic DNA was isolated from blood of healthy individuals using phenol-chloroform extraction methods (18). Six polymorphisms in SLCO1B1, CYP2C19, CYP2C9, and VKORC1 genes (Table 1) were selected according to their effect on enzyme activity (19-21). Genotyping polymorphisms were conducted by real-time polymerase chain reaction (PCR). All of the probes used in this study were specifically designed to detect the SLCO1B1*5, VKORC1 haplotype*2, *3, CYP2C9*2, *3 alleles (LLC “TestGen”, Ulyanovsk, Russia). The primers and probes for these assays are commercially available.

| Table 1. Characterization of the polymorphisms. |
|-----------------------------------------------|
| Gene | SNP | rs     | Drug                                      |
|------|-----|--------|-------------------------------------------|
| SLCO1B1 | SLCO1B1*5, +521T>C | rs4149056 | statins                                   |
| CYP2C19 | CYP2C19*2, +681G>A, CYP2C19*3, +636G>A | rs4244285, rs4986893 | clopidogrel, proton-pump inhibitors, voriconazole |
| CYP2C9 | CYP2C9*2, +430C>T, CYP2C9*3, +1075A>C | rs1799853, rs1057910 | warfarin                                   |
| VKORC1 | VKORC1 haplotype*2 (A), -1639G>A | rs9923231 |                                            |

260
**Statistical analysis**

Deviation from Hardy-Weinberg Equilibrium (HWE) was tested using the online calculator (22). Allele frequencies of various genotypes were compared using the $\chi^2$ test. $P$-value of $\leq 0.05$ was considered statistically significant.

**RESULTS**

The determination of genotype frequencies of the SNPs in question showed compliance of this index to the HWE, indicating the representativeness of the sample. The frequencies of the genotypes of polymorphisms investigated in Yakuts are shown in Table 2. Data on SNPs of previous studies were used to compare the frequency distribution of genotypes in the Yakut population with other populations. The comparative analysis of the genotype frequencies of the polymorphism $SLCO1B1 + 521T > C$ between groups consisting of individuals of the Yakut and the Russian nationality found statistically significant differences ($\chi^2 = 25.52, P < 0.001$). The comparison of the frequencies of genotypes $CYP2C19 + 681G > A$ polymorphism found a significant difference between the Yakuts and the Chinese ($\chi^2 = 45.42, P < 0.001$), and also between the Yakuts and the Russians ($\chi^2 = 8.94, P < 0.05$).

The analysis of the frequency distribution of genotypes of $CYP2C19 + 636G > A$ polymorphism found similar frequencies in groups of the Yakuts and the Chinese. The difference between $CYP2C19 + 636G > A$ genotype frequencies among the Yakuts and the Finnish ($\chi^2 = 10.76, P < 0.001$) were statistically significant. The comparison of the frequencies of $CYP2C9 + 430C > T$ genotypes found a statistically significant difference both between groups of the Yakuts and the Chinese ($\chi^2 = 15.9, P < 0.001$), as well as between groups of the Yakuts and the Finns ($\chi^2 = 8.52, P < 0.05$). At that, it found no significant differences between the frequencies of the SNP in the Yakuts and the Russians. The study of $CYP2C9 + 1075A > C$ polymorphisms in the groups established no significant differences in the frequency of genotypes. There is some frequency difference detected in the polymorphism $VKORC1 - 1639G > A$ between the Yakut and Chinese groups ($\chi^2 = 9.26, P < 0.05$), and between the Yakut and Russian groups ($\chi^2 = 62.15, P < 0.001$).

**DISCUSSION**

It is known that the SNPs frequency distribution can vary greatly between different ethnic groups. As a consequence, the pharmacogenetic test may be clinically significant in the regions where there is a high frequency of the detected allelic variant of the ethnic groups living in the territory. In regions where there is a low frequency of the detectable SNP, the introduction of the pharmacogenetic test will be less relevant. The results obtained in this study of the genotype frequencies of polymorphisms in the population of the Yakuts were more characteristic of the Asian population. Frequencies of minor alleles of polymorphisms in the $CYP2C19 + 681G > A$ and $CYP2C9 + 430C > T$ in the sample we studied were somewhere in the middle between the frequencies in the populations of Asia and Europe. The genotyping work to identify the distribution of genotype frequencies of SNPs associated with a change in pharmacological response is an important condition for the correct interpretation of pharmacogenetic testing using our software application “Lekgen”.

The desktop software application “Lekgen” automatically generates evaluations on the basis of pharmacogenetic test results for drugs of 11 pharmacological groups. The interpretation is based on the algorithms provided by the PharmGKB (33). The software application we developed will reduce the time and labor intensiveness for employees, and as a consequence, will increase the efficiency of their work. The software tool is easy to use due to the structured data, simplicity of navigation and user-friendly menu system, the user manual, based on conventional terms, the possibility of using templates (Fig. 1).
Table 2. Genotype frequencies of SLCO1B1, CYP2C19, CYP2C9, and VKORC1 gene polymorphisms in different ethnic groups.

| SNP        | Genotype | Ethnic groups | Asian | Asian | Caucasian | Caucasian | Reference                                                                 |
|------------|----------|---------------|-------|-------|-----------|-----------|---------------------------------------------------------------------------|
|            |          |               |       |       |           |           |                                                                            |
| SLCO1B1    | TT       |               | 87 (87) | 80 (160) | 61 (349) | 63.9 (299)| Shuev et al. (23); Mei et al. (24); Pasanen et al. (25)                  |
|            | TC       |               | 12 (12) | 18 (36) | 32.5 (186)| 31.8 (149)|                                                                            |
|            | CC       |               | 1 (1)  | 2 (4)  | 6.5 (37)  | 4.3 (20)  |                                                                            |
| CYP2C19    | GG       |               | 69 (158)| 42.6 (243)| 79 (229) | 67.6 (297) | Hilli et al. (26); Peng et al. (27); Sychev et al. (28); Makeeva et al. (29) |
|            | GA       |               | 25.8 (59)| 47.7 (272)| 19.3 (56) | 29 (128)  |                                                                            |
|            | AA       |               | 5.2 (12)| 9.7 (55) | 1.7 (5) | 3.4 (15)  |                                                                            |
|            |          |               |        |        |           |           |                                                                            |
| CYP2C19    | GG       |               | 93.9 (215)| 89.3 (509)| 87 (100) | 87.7 (386) |                                                                            |
|            | GA       |               | 6.1 (14)| 10.7 (61) | 0 (0) | 12.5 (55) |                                                                            |
|            | AA       |               | 0 (0) | 0 (0) | 0 (0) | 1.8 (8) |                                                                            |
| CYP2C9     | CC       |               | 91 (81)| 99.5 (213)| 87.9 (80) | 77.6 (347) |                                                                            |
|            | CT       |               | 7.9 (7)| 0.5 (1) | 9.9 (9) | 21 (94)  |                                                                            |
|            | TT       |               | 1.1 (1)| 0 (0) | 2.2 (2) | 1.3 (6)  |                                                                            |
|            |          |               |        |        |           |           |                                                                            |
| CYP2C9     | AA       |               | 87.6 (78)| 162 (91)| 87.9 (80)| 87.4 (388)|                                                                            |
|            | AC       |               | 11.2 (10)| 16 (9) | 11 (10) | 12.1 (54) |                                                                            |
|            | CC       |               | 1.1 (1)| 0 (0) | 1.1 (1) | 0.45 (2) |                                                                            |
| VKORC1     | GG       |               | 1.1 (1)| 0.6 (1) | 49.5 (45) | 48.5 (48) |                                                                            |
|            | GA       |               | 31.5 (28)| 15.7 (28)| 28.6 (26) | 41.4 (41) |                                                                            |
|            | AA       |               | 67.4 (60)| 83.7 (149)| 22 (20) | 10 (10.1) |                                                                            |

Fig.1. The interface of "Lekgen" software application.

CONCLUSION

The data obtained in our study on frequency carriers of polymorphisms of genes SLCO1B1, CYP2C19, CYP2C9, VKORC1 among the Yakuts may be useful in developing recommendations for a personalized therapy and risk stratification of adverse drug reactions for each region of the Russian Federation.

ACKNOWLEDGEMENTS

This study was supported by the Federal Targeted Programme for Research and
Development in Priority Areas of Advancement of the Russian Scientific and Technological Complex for 2014-2020 (Agreement No. 14.576.21.0070, RFMEFI57614X0070). The funding source had no involvement in the study design, data collection, analysis and interpretation of the data, writing of the report, or in the decision to submit the article for publication.

REFERENCES

1. Aspinall MG, Hamermesh RG. Realizing the promise of personalized medicine. Harv Bus Rev. 2007;85:108-117.
2. Piquette-Miller M, Grant DM. The art and science of personalized medicine. Clin Pharmacol Ther. 2007;81:311-315.
3. Shabaruddin FH, Fleeman ND, Payne K. Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers Med. 2015;8:115-126.
4. Howland RH. Future prospects for pharmacogenetics in the quest for personalized medicine. J Psychosoc Nurs Ment Health Serv. 2012;50:13-16.
5. Haga SB, Allen LaPointe NM, Moaddeb J. Challenges to integrating pharmacogenetic testing into medication therapy management. J Manag Care Spec Pharm. 2015;21:346-352.
6. Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Curr Drug Metab. 2009;10:567-578.
7. Holstein A, Beil W, Kovacs P. CYP2C metabolism of oral antidiabetic drugs impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol. 2012;8:1549-1563.
8. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics. 2002;12:251-263.
9. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001;29:242-251.
10. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoenepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496-526.
11. Jarrar YB, Lee SJ. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy. Drug Metabol Drug Interact. 2014;29:211-220.
12. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008;25:45-51.
13. Kitzmiller JP, Binkley PF, Pandey SR, Suhy AM, Baldassarre D, Hartmann K. Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes. Discov Med. 2013;16:45-51.
14. Gelissen IC, McLachlan AJ. The pharmacogenomics of statins. Pharmacol Res. 2014;88-99-106.
15. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-243.
16. Maksimova N, Hara K, Nikolaeva I, Chun-Feng T, Usui T, Takagi M, et al. Neuroblastoma amplified sequence gene is associated with a novel short stature syndrome characterised by optic nerve atrophy and Pelger-Huët anomaly. J Med Genet. 2010;47:538-548.
17. Maksimova N, Hara K, Miyashia A, Nikolaeva I, Shiga A, Mogovicina A, et al. Clinical, molecular and histopathological features of short stature syndrome with novel CUL7 mutation in Yakuts: new population isolate in Asia. J Med Genet. 2007;44:772-778.
18. Green MR, Sambrook J. Molecular Cloning - A Laboratory Manual. 4th ed. New York: Cold Spring Harbor Press; 2012. P. 47-54.
19. Jeong YH, Abadilla KA, Tantry US, Park Y, Koh JS, Kwak CH, et al. Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. J Thromb Haemost. 2013;11:1194-1197.
20. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25:33-41.
21. de Keyser CE, Peters BJ, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, et al. The SLC01B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics. 2014;24:43-51.
22. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009;169:505-514.
23. Shuev GN, Sychev DA, Khokhlov AA, Grachev AV, Beloshitskaya TA. Frequency of the SLC01B1*5 gene in Russian patients with hyperlipidemia, receiving statins vs. those not receiving statins. Russ J Mol Med. 2014;2:25-28.
24. Mei Y, Wang S, Li Y, Yi S, Wang C, Yang M, et al. Role of SLC01B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of r ocuronium in Chinese patients. J Clin Pharmacol. 2014;55:261-268.
25. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLC01B1 gene in a Finnish population. Eur J Clin Pharmacol. 2006;62:409-415.
26. Hilli J, Rane A, Lundgren S, Bertilsson L, Laine K. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundam Clin Pharmacol. 2007;21:379-386.
27. Peng XE, Chen HF, Hu ZJ, Shi XS. Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China. BMC Med Genet. 2015;16:15.

28. Sychev DA, Denisenko NP, Sizova ZM, Grachev AV, Velikolug KA. The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med. 2015;8:111-114.

29. Makeeva O, Stepanov V, Puzyrev V, Goldstein DB, Grossman I. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics. 2008;9:847-868.

30. Ivashchenko DV, Rusin IV, Grachev AV, Knyazeva GP, Sychev DA. Prevalence of carriage of VKORC1, CYP2C9 and CYP4F2 polymorphisms in Russian patients with high thrombotic risk receiving warfarin in the outpatient settings. Prev Clin Med. 2013;1:100-105.

31. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007;63:1135-1141.

32. Zhuang W, Wu D, Wang Z. Influence of warfarin related genes and non-genetic factors on administrative dose in Shanghai area. Zhonghua Xue Ye Xue Za Zhi. 2014;35:13-17.

33. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414-417.